NovoCure Limited Ordinary Shares (NVCR)
NovoCure Limited is a global oncology company that specializes in developing and commercializing innovative treatments for cancer. Its flagship product, Tumor Treating Fields (TTFields), is a portable therapy device designed to inhibit cancer cell growth. Founded in 2000 and based in Jersey, Channel Islands, NovoCure focuses on harnessing electric fields to target solid tumors, offering a novel approach to cancer therapy.
Company News
Novocure announced positive results from its Phase 3 METIS trial, demonstrating that Tumor Treating Fields (TTFields) therapy can significantly delay brain metastasis progression in non-small cell lung cancer patients without causing neurocognitive side effects.
Wall Street analysts are bullish on Viking Therapeutics and NovoCure, two healthcare stocks with significant potential growth despite recent market challenges in their clinical trials and product launches.
NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shares of 3M, XPeng and other Chinese shares were among the most actively traded ahead of Monday's market open.